Search

Your search keyword '"Petersen, Soeren Lykke"' showing total 9 results
Start Over Author "Petersen, Soeren Lykke"
9 results on '"Petersen, Soeren Lykke"'

1. Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group

Author

Spanjaart, Anne Mea, Ljungman, Per, Tridello, Gloria, Schwartz, Juana, Martinez-Cibrián, Nuria, Barba, Pere, Kwon, Mi, Lopez-Corral, Lucia, Martinez-Lopez, Joaquin, Ferra, Christelle, Di Blasi, Roberta, Ghesquieres, Hervé, Mutsaers, Pim, Calkoen, Friso, Jak, Margot, van Doesum, Jaap, Vermaat, Joost S. P., van der Poel, Marjolein, Maertens, Johan, Gambella, Massimiliano, Metafuni, Elisabetta, Ciceri, Fabio, Saccardi, Riccardo, Nicholson, Emma, Tholouli, Eleni, Matthew, Collin, Potter, Victoria, Bloor, Adrian, Besley, Caroline, Roddie, Claire, Wilson, Keith, Nagler, Arnon, Campos, Antonio, Petersen, Soeren Lykke, Folber, Frantisek, Bader, Peter, Finke, Jurgen, Kroger, Nicolaus, Knelange, Nina, de La Camara, Rafael, Kersten, Marie José, and Mielke, Stephan

Published
2024
Full Text
View/download PDF

2. Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group

Author

MS Hematologie, Cancer, Infection & Immunity, Spanjaart, Anne Mea, Ljungman, Per, Tridello, Gloria, Schwartz, Juana, Martinez-Cibrián, Nuria, Barba, Pere, Kwon, Mi, Lopez-Corral, Lucia, Martinez-Lopez, Joaquin, Ferra, Christelle, Di Blasi, Roberta, Ghesquieres, Hervé, Mutsaers, Pim, Calkoen, Friso, Jak, Margot, van Doesum, Jaap, Vermaat, Joost S.P., van der Poel, Marjolein, Maertens, Johan, Gambella, Massimiliano, Metafuni, Elisabetta, Ciceri, Fabio, Saccardi, Riccardo, Nicholson, Emma, Tholouli, Eleni, Matthew, Collin, Potter, Victoria, Bloor, Adrian, Besley, Caroline, Roddie, Claire, Wilson, Keith, Nagler, Arnon, Campos, Antonio, Petersen, Soeren Lykke, Folber, Frantisek, Bader, Peter, Finke, Jurgen, Kroger, Nicolaus, Knelange, Nina, de La Camara, Rafael, Kersten, Marie José, Mielke, Stephan, MS Hematologie, Cancer, Infection & Immunity, Spanjaart, Anne Mea, Ljungman, Per, Tridello, Gloria, Schwartz, Juana, Martinez-Cibrián, Nuria, Barba, Pere, Kwon, Mi, Lopez-Corral, Lucia, Martinez-Lopez, Joaquin, Ferra, Christelle, Di Blasi, Roberta, Ghesquieres, Hervé, Mutsaers, Pim, Calkoen, Friso, Jak, Margot, van Doesum, Jaap, Vermaat, Joost S.P., van der Poel, Marjolein, Maertens, Johan, Gambella, Massimiliano, Metafuni, Elisabetta, Ciceri, Fabio, Saccardi, Riccardo, Nicholson, Emma, Tholouli, Eleni, Matthew, Collin, Potter, Victoria, Bloor, Adrian, Besley, Caroline, Roddie, Claire, Wilson, Keith, Nagler, Arnon, Campos, Antonio, Petersen, Soeren Lykke, Folber, Frantisek, Bader, Peter, Finke, Jurgen, Kroger, Nicolaus, Knelange, Nina, de La Camara, Rafael, Kersten, Marie José, and Mielke, Stephan

Published
2024

3. Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy:Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group

Author

Spanjaart, Anne Mea, Ljungman, Per, Tridello, Gloria, Schwartz, Juana, Martinez-Cibrián, Nuria, Barba, Pere, Kwon, Mi, Lopez-Corral, Lucia, Martinez-Lopez, Joaquin, Ferra, Christelle, Di Blasi, Roberta, Ghesquieres, Hervé, Mutsaers, Pim, Calkoen, Friso, Jak, Margot, van Doesum, Jaap, Vermaat, Joost S.P., van der Poel, Marjolein, Maertens, Johan, Gambella, Massimiliano, Metafuni, Elisabetta, Ciceri, Fabio, Saccardi, Riccardo, Nicholson, Emma, Tholouli, Eleni, Matthew, Collin, Potter, Victoria, Bloor, Adrian, Besley, Caroline, Roddie, Claire, Wilson, Keith, Nagler, Arnon, Campos, Antonio, Petersen, Soeren Lykke, Folber, Frantisek, Bader, Peter, Finke, Jurgen, Kroger, Nicolaus, Knelange, Nina, de La Camara, Rafael, Kersten, Marie José, Mielke, Stephan, Spanjaart, Anne Mea, Ljungman, Per, Tridello, Gloria, Schwartz, Juana, Martinez-Cibrián, Nuria, Barba, Pere, Kwon, Mi, Lopez-Corral, Lucia, Martinez-Lopez, Joaquin, Ferra, Christelle, Di Blasi, Roberta, Ghesquieres, Hervé, Mutsaers, Pim, Calkoen, Friso, Jak, Margot, van Doesum, Jaap, Vermaat, Joost S.P., van der Poel, Marjolein, Maertens, Johan, Gambella, Massimiliano, Metafuni, Elisabetta, Ciceri, Fabio, Saccardi, Riccardo, Nicholson, Emma, Tholouli, Eleni, Matthew, Collin, Potter, Victoria, Bloor, Adrian, Besley, Caroline, Roddie, Claire, Wilson, Keith, Nagler, Arnon, Campos, Antonio, Petersen, Soeren Lykke, Folber, Frantisek, Bader, Peter, Finke, Jurgen, Kroger, Nicolaus, Knelange, Nina, de La Camara, Rafael, Kersten, Marie José, and Mielke, Stephan

Abstract

COVID-19 has been associated with high mortality in patients treated with Chimeric Antigen Receptor (CAR) T-cell therapy for hematologic malignancies. Here, we investigated whether the outcome has improved over time with the primary objective of assessing COVID-19-attributable mortality in the Omicron period of 2022 compared to previous years. Data for this multicenter study were collected using the MED-A and COVID-19 report forms developed by the EBMT. One-hundred-eighty patients were included in the analysis, 39 diagnosed in 2020, 35 in 2021 and 106 in 2022. The median age was 58.9 years (min-max: 5.2–78.4). There was a successive decrease in COVID-19-related mortality over time (2020: 43.6%, 2021: 22.9%, 2022: 7.5%) and in multivariate analysis year of infection was the strongest predictor of survival (p = 0.0001). Comparing 2022 with 2020–2021, significantly fewer patients had lower respiratory symptoms (21.7% vs 37.8%, p = 0.01), needed oxygen support (25.5% vs 43.2%, p = 0.01), or were admitted to ICU (5.7% vs 33.8%, p = 0.0001). Although COVID-19-related mortality has decreased over time, CAR T-cell recipients remain at higher risk for complications than the general population. Consequently, vigilant monitoring for COVID-19 in patients undergoing B-cell-targeting CAR T-cell treatment is continuously recommended ensuring optimal prevention of infection and advanced state-of-the art treatment when needed.

Published
2024

4. Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis:A study on behalf of the Chronic Malignancies Working Party of EBMT

Author

Polverelli, Nicola, Bonneville, Edouard F., de Wreede, Liesbeth C., Koster, Linda, Kröger, Nicolaus Martin, Schroeder, Thomas, Peffault de Latour, Régis, Passweg, Jakob, Sockel, Katja, Broers, Annoek E.C., Clark, Andrew, Dreger, Peter, Blaise, Didier, Yakoub-Agha, Ibrahim, Petersen, Soeren Lykke, Finke, Jürgen, Chevallier, Patrice, Helbig, Grzegorz, Rabitsch, Werner, Sammassimo, Simona, Arcaini, Luca, Russo, Domenico, Drozd-Sokolowska, Joanna, Raj, Kavita, Robin, Marie, Battipaglia, Giorgia, Czerw, Tomasz, Hernández-Boluda, Juan Carlos, McLornan, Donal P., Polverelli, Nicola, Bonneville, Edouard F., de Wreede, Liesbeth C., Koster, Linda, Kröger, Nicolaus Martin, Schroeder, Thomas, Peffault de Latour, Régis, Passweg, Jakob, Sockel, Katja, Broers, Annoek E.C., Clark, Andrew, Dreger, Peter, Blaise, Didier, Yakoub-Agha, Ibrahim, Petersen, Soeren Lykke, Finke, Jürgen, Chevallier, Patrice, Helbig, Grzegorz, Rabitsch, Werner, Sammassimo, Simona, Arcaini, Luca, Russo, Domenico, Drozd-Sokolowska, Joanna, Raj, Kavita, Robin, Marie, Battipaglia, Giorgia, Czerw, Tomasz, Hernández-Boluda, Juan Carlos, and McLornan, Donal P.

Published
2024

5. Impact of comorbidities and body mass index on the outcomes of allogeneic hematopoietic cell transplantation in myelofibrosis: A study on behalf of the Chronic Malignancies Working Party of EBMT

Author

Polverelli, Nicola, primary, Bonneville, Edouard F., additional, de Wreede, Liesbeth C., additional, Koster, Linda, additional, Kröger, Nicolaus Martin, additional, Schroeder, Thomas, additional, Peffault de Latour, Régis, additional, Passweg, Jakob, additional, Sockel, Katja, additional, Broers, Annoek E. C., additional, Clark, Andrew, additional, Dreger, Peter, additional, Blaise, Didier, additional, Yakoub‐Agha, Ibrahim, additional, Petersen, Soeren Lykke, additional, Finke, Jürgen, additional, Chevallier, Patrice, additional, Helbig, Grzegorz, additional, Rabitsch, Werner, additional, Sammassimo, Simona, additional, Arcaini, Luca, additional, Russo, Domenico, additional, Drozd‐Sokolowska, Joanna, additional, Raj, Kavita, additional, Robin, Marie, additional, Battipaglia, Giorgia, additional, Czerw, Tomasz, additional, Hernández‐Boluda, Juan Carlos, additional, and McLornan, Donal P., additional

Published
2024
Full Text
View/download PDF

6. Donor Lymphocyte Infusion Is a Feasible Way to Improve Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Who Relapse after Allogeneic Stem Cell Transplantation.

Author

Minculescu, Lia, Reekie, Joanne, Petersen, Soeren Lykke, Kornblit, Brian Thomas, Schjoedt, Ida, Andersen, Niels Smedegaard, Andersen, Lisbeth Pernille, Fischer-Nielsen, Anne, Haastrup, Eva Kannik, Friis, Lone Smidstrup, and Sengelov, Henrik

Subjects
STEM cell transplantation, ACUTE myeloid leukemia, MYELODYSPLASTIC syndromes, OVERALL survival, LYMPHOCYTES
Abstract

Introduction: Donor lymphocyte infusion (DLI) is used to induce remission in patients who relapse after allogeneic stem cell transplantation (allo-HSCT). During the last decade, the hypomethylating agent Azacitidine has been used together with DLI for a synergistic graft-versus-leukemia (GVL) effect. Here, we report results of DLI/Azacitidine treatment from a retrospective single-center study. Methods: Fifty AML/MDS patients treated for relapse after allo-HSCT between 2001 and 2020 with DLI at the Department of Hematology, at Rigshospitalet, Copenhagen University Hospital were included for analyses. A subgroup of patients who obtained complete remission (CR) after reinduction chemotherapy, received DLI in combination with low-dose (32 mg/m2) Azacitidine. Results: Overall survival in all patients after DLI treatment was 59% at 2 years and 20% at 5 years. Relapse-free survival in patients in CR prior to DLI was 32% after 2 years and 7% after 5 years. In the DLI + low-dose-Azacitidine group, 5-year relapse-free survival was 40%. Conclusion: DLI remains an effective treatment in post-transplant relapse leaving one-fifth of patients' long-term survivors. Our results support the concomitant use of low-dose Azacitidine in the future use of DLI in order to enhance the GVL effect of donor lymphocytes. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Donor Lymphocyte Infusion Is a Feasible Way to Improve Survival in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Who Relapse after Allogeneic Stem Cell Transplantation

Author

Minculescu, Lia, primary, Reekie, Joanne, additional, Petersen, Soeren Lykke, additional, Kornblit, Brian Thomas, additional, Schjoedt, Ida, additional, Andersen, Niels Smedegaard, additional, Andersen, Lisbeth Pernille, additional, Fischer-Nielsen, Anne, additional, Haastrup, Eva Kannik, additional, Friis, Lone Smidstrup, additional, and Sengelov, Henrik, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results